PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy

Koji Matsumoto, Meiko Nishimura, Takuma Onoe, Hideki Sakai, Yusaku Urakawa, Takashi Onda, Nobuo Yaegashi

Research output: Contribution to journalReview articlepeer-review

5 Citations (Scopus)

Abstract

After a brief summary of the current status of poly-ADP ribose polymerase (PARP) inhibitors for ovarian cancer, we summarize the current status of PARP inhibitors for BRCA wild type ovarian cancer, especially regarding gene alterations other than BRCA, homologous recombination deficiency (HRD), and combinations. Discussion of gene alterations other than BRCA include the results of multiple gene panels studying homologous recombination repair deficiency genes and cancer susceptibility genes, and influences of these alterations on efficacy of PARP inhibitors and cancer susceptibility. Discussions of HRD include the results of phase three trials using HRD assay, the definition of HRD assays, and the latest assays. Discussions of combinations include early phase trial results and ongoing trials combining PARP inhibitors with immune checkpoint inhibitors, anti-angiogenic agents, and triplets.

Original languageEnglish
Pages (from-to)703-707
Number of pages5
JournalJapanese journal of clinical oncology
Volume49
Issue number8
DOIs
Publication statusPublished - 2019 Aug 1

Keywords

  • BRCA wild type
  • Genetic counseling
  • HRD
  • LOH
  • PARP inhibitors

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy'. Together they form a unique fingerprint.

Cite this